Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
07 Junho 2023 - 9:15AM
Royalty Pharma plc (Nasdaq: RPRX) today announced that it is
scheduled to present at the Goldman Sachs 44th Annual Global
Healthcare Conference on June 13, 2023 at 5:00 p.m. ET / 2:00 p.m.
PT.
The webcast will be accessible from Royalty Pharma’s “Events”
page at
https://www.royaltypharma.com/investors/news-and-events/events. The
webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri and
Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas
and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s
Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi,
Gilead’s Trodelvy, and 11 development-stage product candidates. For
more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6637ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Royalty Pharma (NASDAQ:RPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024